# EDGAR Filing Document

**Accession Number:** 0001347242
**File Stem:** 0001753926-26-000577
**Filing Date:** 2026-3
**Character Count:** 6966
**Document Hash:** 645e2303bcc11a5ef9c3274ab8d9bf77
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-26-000577.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001753926-26-000577

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260330

**ITEM INFORMATION**: Bankruptcy or Receivership

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LIPELLA PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001347242
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41575
- **FILM NUMBER:** 26816276

**BUSINESS ADDRESS:**
- **STREET 1:** 400 N LEXINGTON ST
- **STREET 2:** STE LL103
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15208
- **BUSINESS PHONE:** 412-901-0315

**MAIL ADDRESS:**
- **STREET 1:** 400 N LEXINGTON ST
- **STREET 2:** STE LL103
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15208

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LIPELLA PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20051219

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 30, 2026**

**Lipella Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41575** | **20-2388040** |
| (State or other jurisdiction <br> of incorporation) | (Commission File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **7800 Susquehanna St., Suite 505**<br> **Pittsburgh, PA** | **15208** |
| (Address of registrant's principal executive office) | (Zip code) |

---

Registrant's telephone number, including area code: **(412) 894-1853**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.03 Bankruptcy or Receivership**

On **[Filing Date]**, **[Company Name, Inc.]** (the "Company") and certain of its subsidiaries (collectively, the "Debtors") filed voluntary petitions for relief under **Chapter 11 of Title 11 of the United States Code** in the United States Bankruptcy Court for the Western District of Pennsylvania (the "Bankruptcy Court").

**Cautionary Note Regarding Chapter 11 Case**

The Company cautions that trading in the Company's common stock during the pendency of the Chapter 11 case is highly speculative and poses substantial risks. Trading prices for the Company's common stock may bear little or no relationship to the actual recovery, if any, by holders of the Company's common stock in the Chapter 11 Cases.

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated March 30, 2026](g085465_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 30, 2026 | **Lipella Pharmaceuticals Inc.** | **Lipella Pharmaceuticals Inc.** |
|  | By: | */s/ Jonathan Kaufman* |
|  |  | Name: Jonathan Kaufman<br> Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Press Release**

**FOR IMMEDIATE RELEASE**

**Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11**

**[Pittsburgh, Pennsylvania] — [March 30, 2026]** — Lipella Pharmaceuticals Inc. ("Lipella" or the "Company"), a clinical-stage biotechnology company, announced today that it filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Western District of Pennsylvania (the "Court"). The Company intends to undergo a 363 sale process under Chapter 11 in order to maximize value for creditors.

In connection with the Chapter 11 cases, the Company expects to seek customary "first-day" relief that, if approved by the Court, would allow it to continue day-to-day operations, including maintaining cash management systems and paying employee wages and benefits in the ordinary course.

The Company will provide updates as appropriate throughout the restructuring process.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the Company's expectations and intentions relating to the Chapter 11 process, ongoing operations, strategic alternatives, and related matters. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others, the Company's ability to obtain Court approval with respect to motions in the Chapter 11 cases, the Company's ability to maintain operations during the Chapter 11 process, the effects of the Chapter 11 filing on stakeholders, and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

**Additional Information**

Additional information regarding the Chapter 11 filing, including Court filings and other case information, may be available through the Court's docket.

TADMS:21257425-1:044116-208154